DIN: 07144684

Sugy

ıdited ny for d on

e and

d on

estor

bsite

ate com

019

ED

147 ure eby

tra

CIN: L24230GJ1972PLC002126

Website: www.torrentpharma.com

Email: investorservices@torrentpharma.com Fax: +91 79 26582100

TORRENT PHARMACEUTICALS LIMITED

Registered Office:

Torrent House, Off Ashram Road, Ahmedabad - 380 009, Gujarat, India,

Ph.: +91 79 26599000

Extract of Consolidated Financial Results for the Quarter and Year ended 31-Mar-2019

[₹ in Crores except per share data]

	- P- Pot Share Gata		
Particulars	Quarter Ended 31-Mar-2019	Year Ended 31-Mar-2019	Quarter Ended 31-Mar-2018
Programme and posterior of the second of the	Audited (Refer Note 2)	Audited	Audited (Refer Note 2)
Total Income from operations (net)	1856	7673	1708
Net Profit / (Loss) for the period before tax and exceptional items	207	919	134
Net Profit / (Loss) for the period before tax and after exceptional items	(150)	562	134
Net Profit / (Loss) for the period after tax and exceptional items	(152)	436	228
Total Comprehensive Income (after tax)	(99)	469	184
Equity Share Capital	84.62	84.62 '	84.62
Other Equity excluding Revaluation Reserve*	HE ALTERNATION OF THE PARTY OF	4639	Windships was
Earnings per share (of ₹ 5/- each) before exceptional items net of taxes			AND ADDRESS NATIONAL
Basic & Diluted	7.72	42.45	12.55
(Loss) / Earnings per share (of ₹ 5/- each) after exceptional items net of taxes	A to be read of	12.45	13.55
Basic & Diluted	(8.95)	25.78	13.55

^{*} Other Equity excluding Revaluation Reserve as on 31-Mar-2018 was ₹ 4537 crores.

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited:

The state of the s	American COLON COLON COLON		[₹ in Crores]	
Particulars	Quarter Ended 31-Mar-2019	Year Ended 31-Mar-2019	Quarter Ended 31-Mar-2018	
Net income from operations	1357	5762	1332	
Profit before tax	255	935	83	
Profit after tax	164	745.	220	
Total Comprehensive Income (after tax)	204	768	189	

- 2 The figures for the quarter ended 31-Mar-2019 and 31-Mar-2018 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year, which were subject to limited review.
- 3 The Board of Directors in their meeting held on 20-May-2019, declared a final equity dividend of ₹ 4.00 per equity share.
- 4 The above is an extract of the detailed format of Financial Results for the quarter and year ended 31-Mar-2019 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.

Place: Ahmedabad, Gujarat Date: 20-May-2019